id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2007-A-0099-0005,FDA,FDA-2007-A-0099,"Response Letter from FDA CDER to GlaxoSmithKline, Wilmer Cutler Pickering Hale and Dorr LLP,  Ropes & Gray LLP,  Novo Nordisk Inc. and Finnegan, Henderson, Farabow, Garrett & Dunner, LLP",Other,Response(s),2020-06-01T04:00:00Z,2020,6,2020-06-01T04:00:00Z,,2020-06-02T02:12:05Z,,0,0,09000064846c252f
FDA-2007-A-0099-0004,FDA,FDA-2007-A-0099,Ropes & Grays LLP - Comment,Other,AP-Advisory Opinion Petition,2008-08-08T04:00:00Z,2008,8,2008-08-08T04:00:00Z,,2008-08-08T21:11:38Z,,0,0,0900006480429d78
FDA-2007-A-0099-0003,FDA,FDA-2007-A-0099,Advisory Opinion Petition form AstraZeneca Ropes and Gray LLP,Other,Advisory Opinion Petition,2008-07-24T04:00:00Z,2008,7,2008-07-24T04:00:00Z,,2014-01-20T23:53:15Z,,0,0,090000648069379f
FDA-2007-A-0099-0002,FDA,FDA-2007-A-0099,Letter from FDA CDER Interim Response to AstraZeneca Ropes and Gray LLP,Other,Letter(s),2007-12-20T05:00:00Z,2007,12,,,2014-01-21T00:25:14Z,,0,0,0900006480429d7a
FDA-2007-A-0099-0001,FDA,FDA-2007-A-0099,FDA/DDM Acknowledgement Letter to AstraZeneca Ropes and Gray LLP,Other,Acknowledgement Letter/Receipt,2007-06-28T04:00:00Z,2007,6,,,2014-01-20T23:56:18Z,,0,0,0900006480429d75